Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente) - PubMed (original) (raw)
Meta-Analysis
Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente)
E Mari et al. Ann Oncol. 2000 Jul.
Free article
Abstract
Background: Several studies have investigated the possible role of the adjuvant chemotherapy after curative resection for gastric cancer failing to show a clear indication; previous meta-analyses suggested small survival benefit of adjuvant chemotherapy, but the statistical methods used were open to criticisms.
Materials and methods: Randomised trials were identified by means of Medline and CancerLit and by selecting references from relevant articles. Systematic review of all randomised clinical trials of adjuvant chemotherapy for gastric cancer compared with surgery alone, published before January 2000, were considered. Pooling of data was performed using the fixed effect model. Death for any cause was the study endpoint. The hazard ratio and its 95% confidence intervals (95% CI), derived according to the method of Parmar, were the statistics chosen for summarising the relative benefit of chemotherapy versus control.
Results: Overall 20 articles (21 comparisons) were considered for analysis. Three studies used single agent chemotherapy, seven combination of 5-fluorouracil (5-FU) with anthracyclin, ten combination of 5-FU without anthracyclines. Information on 3658 patients, 2180 deaths, was collected. Chemotherapy reduced the risk of death by 18% (hazard ratio 0.82, 95% CI: 0.75-0.89, P < 0.001). Association of Anthracyclines to 5-FU did not show a statistically significant improvement when compared with the effect of the other regimens.
Conclusions: Chemotherapy produces a small survival benefit in patients with curatively resected gastric cancer. However, taking into account the limitations of literature based meta-analyses, adjuvant chemotherapy is still to be considered as an investigational approach.
Comment in
- Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer.
Gianni L, Panzini I, Tassinari D, Mianulli AM, Desiderio F, Ravaioli A. Gianni L, et al. Ann Oncol. 2001 Aug;12(8):1178-80. Ann Oncol. 2001. PMID: 11583204 Clinical Trial. No abstract available.
Similar articles
- [Effectiveness of precautionary chemotherapy in gastric cancer].
Rimassa L, Campagnoli E, Biancofiore G. Rimassa L, et al. Tumori. 2000 Sep-Oct;86(5 Suppl 2):S5-13. Tumori. 2000. PMID: 11195303 Review. Italian. - Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials.
Earle CC, Maroun JA. Earle CC, et al. Eur J Cancer. 1999 Jul;35(7):1059-64. doi: 10.1016/s0959-8049(99)00076-3. Eur J Cancer. 1999. PMID: 10533448 - A systematic overview of chemotherapy effects in gastric cancer.
Janunger KG, Hafström L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care. Janunger KG, et al. Acta Oncol. 2001;40(2-3):309-26. doi: 10.1080/02841860151116385. Acta Oncol. 2001. PMID: 11441938 Review. - Chemotherapy for advanced gastric cancer.
Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, Fleig WE. Wagner AD, et al. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004064. doi: 10.1002/14651858.CD004064.pub2. Cochrane Database Syst Rev. 2005. PMID: 15846694 Updated. Review. - Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials.
Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, Van de Velde CJ. Hermans J, et al. J Clin Oncol. 1993 Aug;11(8):1441-7. doi: 10.1200/JCO.1993.11.8.1441. J Clin Oncol. 1993. PMID: 8336183
Cited by
- Promoter Methylation of DNA Repair Genes Predicts Disease-free Survival of Gastric Adenocarcinoma after Adjuvant Radiotherapy.
An N, Yu Z, He XJ, Zhao YY, Yu L, Zhang YC, Lu HJ, Yang X. An N, et al. Mol Ther Oncolytics. 2020 Jun 9;18:109-117. doi: 10.1016/j.omto.2020.06.006. eCollection 2020 Sep 25. Mol Ther Oncolytics. 2020. PMID: 32671186 Free PMC article. - Advances in the pharmacological treatment of gastro-oesophageal cancer.
Wagner AD, Wedding U. Wagner AD, et al. Drugs Aging. 2009;26(8):627-46. doi: 10.2165/11315740-000000000-00000. Drugs Aging. 2009. PMID: 19685930 Review. - Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial.
Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JW. Bramhall SR, et al. Br J Cancer. 2002 Jun 17;86(12):1864-70. doi: 10.1038/sj.bjc.6600310. Br J Cancer. 2002. PMID: 12085177 Free PMC article. Clinical Trial. - Recent advances in the treatment of gastric cancer.
Sun W, Haller DG. Sun W, et al. Drugs. 2001;61(11):1545-51. doi: 10.2165/00003495-200161110-00002. Drugs. 2001. PMID: 11577792 Review. - A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer.
Lee SS, Jeung HC, Chung HC, Noh SH, Hyung WJ, Ahn JY, Rha SY. Lee SS, et al. Invest New Drugs. 2012 Feb;30(1):357-63. doi: 10.1007/s10637-010-9515-2. Epub 2010 Aug 24. Invest New Drugs. 2012. PMID: 20734110 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical